Immunotherapy for hepatocellular carcinoma following thermal ablation

Journal of B.U.ON.

Volumn 19, Issue 4, 2014, Pages 867-871

  Li, Xin ^a   Liang, Ping ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; Immunotherapy; Thermal ablation; Tumor associated antigens

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; SSX 1 PROTEIN; SSX 2 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ABLATION THERAPY; ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CD4 CD8 RATIO; ERYTHROCYTE FUNCTION AND CHARACTERISTICS; HUMAN; IMMUNE STATUS; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; THERMAL ABLATION; CATHETER ABLATION; IMMUNOTHERAPY; LIVER TUMOR; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 84921909426     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
2. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-773.
3. Breous EI, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011;54:830-834.
4. Dong B, Zhang J, Liang P et al. Influencing factors of local immunocyte infiltration in hepatocellular carcinoma tissues pre- and post-percutaneous microwave coagulation therapy. Zhonghua Yi Xue Za Zhi 2002;82:393-397.
5. Kuang M, Liu SQ, Saijo K et al. Microwave tumour coagulation plus in situ treatment with cytokine-microparticles: induction of potent anti-residual tumour immunity. Int J Hyperthermia 2005;21:247-257.
6. Rhim H, Goldberg SN, Dodd GD 3rd et al. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. Radiographics 2001;21(Spec No):S17-S35
7. McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Intervent Radiol 2013;30:49-55.
8. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics 2005;25(Suppl 1):S69-S83.
9. Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences. Curr Probl Diagn Radiol 2009;38:135-143.
10. Tanaka M, Sato M. Microwave heating of water, ice, and saline solution: molecular dynamics study. J Chem Phys 2007;126:034509.
11. Liang P, Yu J, Lu MD. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol 2013;19:5430-5438.
12. Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Rev Anticancer Ther 2009;9:1499-1510.
13. den Brok MH, Sutmuller RP, van der Voort R et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004;64:4024-4029
14. Zhou P, Liang P, Dong B et al. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther 2011;11:450-456.
15. Lee WC, Wu TJ, Chou HS et al. The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma. Surgery 2012;151:213-222.
16. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-2339.
17. Wang F, Jing X, Li G et al. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int 2012;32:644-655.
18. Chen KJ, Zhou L, Xie HY et al. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol 2012;29:1817-1826.
19. Mathai AM, Kapadia MJ, Alexander J et al. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma. Am J Surg Pathol 2012;36:980-986.
20. Chew V, Chen J, Lee D et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012;61:427-438.
21. Motomura T, Shirabe K, Mano Y et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013;58:58-64.
22. Dong BW, Zhang J, Liang P et al. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia 2003;19:119-233.
23. Siegel I, Liu TL, Gleicher N. The red-cell immune system. Lancet 1981;2:556-559.
24. Meng WS, Butterfield LH, Ribas A et al. alpha-Fetoprotein-speciflc tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001;61:8782-8786.
25. Thimme R, Neagu M, Boettler T et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 2008;48:1821-1833.
26. Xu H, Gu N, Liu ZB et al. NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett 2012;3:39-44.
27. Zhang WM, Xiao G, Xie D et al. Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma. Ai Zheng 2005;24:622-626.
28. Lu Y, Wu LQ, Lu ZH et al. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma. Chin Med J (Engl) 2007;120:1042-1046.
29. Ayyoub M, Rimoldi D, Guillaume P et al. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 2003;63:5601-5606.
30. Bricard GI, Bouzourene H, Martinet O et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005;174:1709-1716.
31. Xiao WK, Qi CY, Chen D et al. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer 2014;14:104.
32. Xu C, Yan Z, Zhou L et al. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:1417-1424.
33. Mizukoshi E, Nakamoto Y, Marukawa Y et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006;43:1284-1294.
34. Kong SY, Park JW, Kim JO et al. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009;135:1091-1098.
35. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002;29:12-17.
36. Herberman RB. Cancer immunotherapy with natural killer cells. Semin Oncol 2002;29:27-30.
37. Ge NL, Ye SL, Zheng N et al. Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines. World J Gastroenterol 2003;9:2182-2185.
38. Asahina Y, Tsuchiya K, Nishimura T et al. a-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253-1262.
39. Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr Mol Med 2011;11:564-581.
40. Sawada Y, Yoshikawa T, Nobuoka D et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18:3686-3696.
41. Nobuoka D, Yoshikawa T, Sawada Y et al. Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother 2013;9:210-212.
42. Kanai T, Monden M, Takeda T et al. Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2. Gan To Kagaku Ryoho 1993;20:1457-1460.
43. Kawata A, Une Y, Hosokawa M et al. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 1992;22:256-263.
44. Pan K, Li YQ, Wang W et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 2013;20:4305-4311.
45. Pan K, Wang QJ, Liu Q et al. The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumour Biol 2014;35:701-707.
46. Xin Li, Ping Liang, Mingan Yu et al. The Effect of Adoptive Immunotherapy after Percutaneous Microwave Ablation in Recurrent Hepatocellular Carcinoma Patients with Hepatitis B: A Preliminary Study. Am J Clin Cancer Res 2013;2:1-13.